Search the Newsreel

Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Madrigal Pharmaceuticals (MDGL) drew attention after its second quarter 2026 earnings release, which highlighted Rezdiffra sales growth, stronger patient uptake, a smaller than …

Arthur J. Gallagher & Co. (NYSE:AJG) Price Target Raised to $310.00

Royal Bank of Canada has increased its price target for Arthur J. Gallagher & Co. (NYSE:AJG) to $310.00, maintaining an "outperform" rating and implying a 23% upside. This comes after the financial services provider reported adjusted quarterly EPS of $2.84, beating estimates, and a …

Mizuho Raises Arthur J. Gallagher & Co. (NYSE:AJG) Price Target to $300.00

Mizuho has increased its price target for Arthur J. Gallagher & Co. (NYSE:AJG) to $300.00 from $287.00, maintaining an "outperform" rating and suggesting a 19.58% upside. Despite the company reporting adjusted EPS of $2.84, which slightly exceeded estimates, its revenue of $3.95 billion missed …

Soter Insure Secures Series B Funding Led By Galaxy To Scale Its Digital Asset Insurance Solutions

Soter Insure, a provider of digital asset insurance products, has announced the first close of its Series B funding round, led by Galaxy Digital with new participation from Coinbase Ventures and Franklin Templeton. This funding, totaling $23.5 million upon final close, will support the …

Arthur J. Gallagher presenta unos resultados del segundo trimestre sin grandes sorpresas, según RBC Capital Markets

Vanguard Capital Management (NYSE: SPCE) discloses 5.13M-share Virgin Galactic stake

Vanguard Capital Management has reported a beneficial ownership of 5,133,627 shares of Virgin Galactic Holdings Inc. (NYSE: SPCE), representing a 5.09% stake in the company as of June 30, 2026. The filing indicates Vanguard has sole voting power over 676,353 shares and sole dispositive …

Compared to Estimates, Huntington Ingalls (HII) Q2 Earnings: A Look at Key Metrics

Huntington Ingalls (HII) reported $3.42 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 10.9%. EPS of $5.27 for the same period compares to $3.86 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $3.14 …

Huntington Ingalls Industries (NYSE:HII) Stock Rating Upgraded by Wolfe Research

Wolfe Research upgraded Huntington Ingalls Industries (NYSE:HII) from "peer perform" to "outperform" with a $364 price target, suggesting a 13.85% upside. This upgrade follows a strong quarter where HII beat EPS and revenue estimates, with EPS of $5.27 against $3.79 consensus and revenue of …

Galmed Pharmaceuticals Ltd (GLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Galmed Pharmaceuticals Ltd (GLMD), focusing on its volatility, financial risk, and investment risk. It highlights the company's current risk assessment score, its beta value relative to the S&P 500 index, and various metrics related to return, drawdown, …

Arthur J. Gallagher & Co. (NYSE:AJG) Stock Price Expected to Rise, Keefe, Bruyette & Woods Analyst Says

Keefe, Bruyette & Woods has raised their price target for Arthur J. Gallagher & Co. (NYSE:AJG) to $271, maintaining a "market perform" rating, with a potential upside of 5.7%. While the company beat adjusted EPS estimates in its latest quarter, revenue fell short, and …

Arthur J. Gallagher (AJG) Reports Q2 Results, Is The 9% Undervalued View Still Convincing?

Huntington Ingalls Industries Q2 Earnings Call Highlights

Key Points Interested in Huntington Ingalls Industries, Inc.? Here are five stocks we like better. Strong second-quarter results: HII reported $3.4 billion in sales and diluted EPS of $5.27, while shipbuilding revenue rose 16% to $2.7 billion. Contract awards totaled $6.7 billion. Shipbuilding outlook …

LegalZoom.com Inc (LZ) Financial Health: Profitability & Balance Sheet Analysis

LegalZoom.com Inc (LZ) currently holds a strong financial health score of 8.53,

Quantinno Capital Management LP Buys 39,893 Shares of Arthur J. Gallagher & Co. $AJG

Quantinno Capital Management LP increased its stake in Arthur J. Gallagher & Co. by 34.1% in the first quarter, purchasing an additional 39,893 shares. The firm now owns 156,950 shares valued at $33,992,000. Several other institutional investors also adjusted their positions in AJG, while …

Arthur J. Gallagher & Co. $AJG Shares Sold by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund has reduced its stake in Arthur J. Gallagher & Co. (NYSE:AJG) by 28.8% in the first quarter, selling 6,513 shares. Despite this, other institutional investors like Norges Bank and T. Rowe Price Investment Management Inc. significantly increased …

Renaissance Technologies LLC Has $16.59 Million Stock Position in Arthur J. Gallagher & Co. $AJG

Renaissance Technologies LLC significantly increased its stake in Arthur J. Gallagher & Co. by 1,673.1% in the first quarter, now holding 76,600 shares valued at $16.59 million. The company reported strong Q2 adjusted earnings of $2.84 per share, beating estimates, and a 24.3% year-over-year …

Galaxy Digital Inc. (NASDAQ:GLXY) Given Average Rating of "Moderate Buy" by Brokerages

Galaxy Digital Inc. (NASDAQ:GLXY) has received an average rating of "Moderate Buy" from fourteen brokerages, with ten recommending a buy, two a hold, and two a sell. The average 12-month price target is $39.58, significantly above its current trading price of $21.52. The company …

Amundi Boosts Stock Position in Arthur J. Gallagher & Co. $AJG

Amundi increased its stake in Arthur J. Gallagher & Co. by 1.0% in the first quarter, now owning 939,835 shares worth over $203 million. Other institutional investors also adjusted their positions, and Wall Street analysts have largely given the stock "Buy" or "Moderate Buy" …

Galmed Pharmaceuticals (NASDAQ: GLMD) granted new deadline to meet $1 bid rule

MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth

Arthur J. Gallagher (AJG) Could Be 9% Undervalued After Q2 Revenue Growth

AgroGalaxy (AGXY3) adia balanço do 4T25 e resultados de 2026; veja novas datas

Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving Average - Here's Why

Galaxy Surfactants Limited (GALAXYSURF.NS) stock price, news, quote and history

Galan Lithium Surges 12% — Has the Lithium Comeback Finally Begun?

Huntington Ingalls Industries (HII) Stock Rises On Shipbuilding Strength And Margin Gains

Huntington Ingalls Industries (NYSE:HII) Posts Quarterly Earnings Results, Beats Expectations By $1.48 EPS

ASX Income Lens: Exploring Regal Partners (ASX:RPL) Yield, Strategy and Distribution Factors

Donegal reports $22.3m net income as CoR improves to 95.6%

Donegal Group Inc. reported a second-quarter net income of $22.3 million, or 60 cents per diluted Class A share, an increase from $16.9 million in the prior year. The company's combined ratio improved to 95.6% from 97.7%, and its annualized return on average equity …

LegalZoom Number of Employees 2026 | Employee Count & Headcount Data

LegalZoom.com, Inc. (LZ) had approximately 1,192 total employees worldwide as of March 2026, a 16.1% decline from 2023. The company is actively hiring, with 94 active job postings in 2026, and the majority of its workforce (80.4%) is based in the United States. Employee …

Regal Rexnord Corp (RRX) Stock Up 8.0% but GF Value Says Overval

Regal Rexnord Corp (RRX) shares recently rose 8.0% to $202.59, but GuruFocus' GF Value™ indicates the stock is significantly overvalued by 31.3% with an intrinsic value estimate of $154.25. Despite a strong GF Score™ of 84/100, insider selling of $8.3 million and no buying …

Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Galectin Therapeutics Inc (GALT), detailing its support, resistance levels, and various technical indicators. It presents a summary of buy, sell, and neutral signals from indicators like MACD, RSI, and moving averages, concluding with a neutral overall signal …

Regal Partners Global Investments Cancels Shares Following On-Market Buy-Back

Is Stronger Rezdiffra Momentum and New Patents Altering The Investment Case For Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals reported Q2 2026 results with widened net losses but stronger-than-expected sales of Rezdiffra and new patent protections extending into the 2040s for resmetirom. These developments reinforce the company's investment narrative, suggesting it can maintain its first-in-class position in MASH. While near-term sales …

Is Huntington Ingalls Industries Inc (HII) Overvalued After 14.1% Rally? GF Value Says Overvalued

Huntington Ingalls Industries Inc (HII) recently saw its shares rise by 14.1% to $319.90. However, GuruFocus' GF Value™ indicates the stock is 11.0% overvalued at $288.25, suggesting potential risk. While HII boasts a strong GF Score™ of 80/100, driven by profitability and growth, its …

Earnings call transcript: Arthur J. Gallagher posts Q2 2026 EPS beat, shares fall

Arthur J. Gallagher & Co. reported strong Q2 results, with combined Brokerage and Risk Management revenue growing 24%, including 6% organic growth, and marking its 25th consecutive quarter of double-digit adjusted EBITAC growth. The company maintained its 2026 organic growth target of 6% and …